This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Tenax Therapeutics’s 8K filing here.
About Tenax Therapeutics
Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Further Reading
- Five stocks we like better than Tenax Therapeutics
- Why Invest in 5G? How to Invest in 5G Stocks
- Is Confluent the Next Big Winner in AI-Powered Data Streaming?
- How to Use the MarketBeat Excel Dividend Calculator
- Under-the-Radar AI Stock Vertiv Up 160% and Climbing
- Roth IRA Calculator: Calculate Your Potential Returns
- Is MARA a Safe Way to Get Exposure to the Bitcoin Rally?
